Wells Fargo & Company Cyclo Therapeutics, Inc. Put Options Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding CYTH
# of Institutions
22Shares Held
2.16MCall Options Held
0Put Options Held
0-
Epiq Capital Group, LLC San Francisco, CA854KShares$1.07 Million0.47% of portfolio
-
Founders Fund V Management, LLC San Francisco, CA481KShares$600,8853.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA397KShares$495,8220.0% of portfolio
-
Geode Capital Management, LLC Boston, MA160KShares$199,6860.0% of portfolio
-
Founders Fund Vi Management, LLC San Francisco, CA110KShares$137,52857.89% of portfolio
About Cyclo Therapeutics, Inc.
- Ticker CYTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 8,439,440
- Market Cap $10.5M
- Description
- Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...